Zhongshan Laibo Ruichen Biomedicine Co., Ltd.

Home>

Rabpharma Successfully Recognized as a National High-tech Enterprise

Rabpharma's RAB001 Secures Additional IND Clearance, Expanding into Osteoarthritis

Patient enrollment has been completed for the RAB001 Phase II clinical trial!

Rabpharma Successfully Closes Oversubscribed Series A++ Funding Round to Accelerate R&D Progress

Early-Stage Osteonecrosis Phase II Clinical Trial Patient Recruitment